Finance

Lists
APGE:NASDAQ
Apogee Therapeutics Inc
$134.71
0.00%
(0.00) 1D
Aug 19, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for APGE...
Mkt. cap
10.20B
Avg. vol.
1.22M
Volume
187.00
52-wk high
$134.88
52-wk low
$35.39
EPS
-$4.34
Beta
0.34
Shares outstanding
62.14M
No. of employees
261
Mkt. cap
10.20B
Avg. vol.
1.22M
Volume
187.00
52-wk high
$134.88
52-wk low
$35.39
EPS
-$4.34
Beta
0.34
Shares outstanding
62.14M
No. of employees
261
News stories
From web sources and news partners
About Apogee Therapeutics Inc
CEO-
Employees261
Founded2022
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websiteapogeetherapeutics.com
Analyst ratings
Based on 15 analysts giving stock ratings to APGE in the past 3 months
Hold
Buy
3
Hold
12
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for APGE in the last 3 months.
Highest
Current $134.71
$137.00 (+1.70%)
Average
$131.18 (-2.62%)
Lowest
$89.00 (-33.93%)
Analyst
Recommendation
Action
Price target
Projected
Date
Geoff Meacham
Citi
Hold
Maintained
$135.00
+0.2%
08/13/2026
Danielle Brill
Truist Financial
Hold
Maintained
$135.00
+0.2%
08/13/2026
Edward Nash
Canaccord Genuity
Hold
Reiterated
$135.11
+0.3%
08/11/2026
David Nierengarten
Wedbush
Hold
Maintained
$135.00
+0.2%
08/11/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$135.00
+0.2%
08/10/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$133.00
-1.3%
06/29/2026
Joseph Catanzaro
Mizuho Securities
Hold
Downgraded
$135.00
+0.2%
06/24/2026
Tyler Van Buren
TD Cowen
Hold
Downgraded
-
-
06/24/2026
Seamus Fernandez
Guggenheim
Hold
Downgraded
-
-
06/23/2026
Michael Yee
UBS
Hold
Downgraded
$135.11
+0.3%
06/23/2026
David Hoang
Deutsche Bank
Hold
Downgraded
$135.00
+0.2%
06/23/2026
Adam Vogel
Craig-Hallum
Hold
Downgraded
$135.11
+0.3%
06/22/2026
Julian Harrison
BTIG
Buy
Reiterated
$137.00
+1.7%
06/19/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
$131.00
-2.8%
06/11/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
$89.00
-33.9%
06/10/2026
Qize Ding
Rothschild & Co Redburn
Buy
Initiated
$140.00
+3.9%
05/01/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
54.18M
58.44M
60.82M
67.30M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17.10M
19.61M
21.95M
24.34M
Operating expense
71.28M
78.06M
82.77M
91.64M
Total operating expenses
71.28M
78.06M
82.77M
91.64M
Operating income
-71.28M
-78.06M
-82.77M
-91.64M
Other non operating income
-
-
-
-
EBT including unusual items
-64.96M
-69.32M
-74.03M
-85.78M
EBT excluding unusual items
-64.96M
-69.32M
-74.03M
-81.42M
Income tax expense
61.00K
62.00K
79.00K
78.00K
Effective tax rate
-0.09%
-0.09%
-0.11%
-0.09%
Other operating expenses
-
-
-
-
Net income
-65.02M
-69.39M
-74.11M
-85.85M
Net profit margin
-
-
-
-
Earnings per share
-1.11
-1.03
-1.06
-1.08
Interest and investment income
6.32M
8.73M
8.74M
11.81M
Interest expense
-
-
-
-1.58M
Net interest expenses
6.32M
8.73M
8.74M
10.23M
Depreciation and amortization charges
-
-
-
-
EBITDA
-70.87M
-77.65M
-82.36M
-91.23M
Gain or loss from assets sale
-
-
-
43.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps